A breakthrough treatment combination is poised to spare bladder cancer patients from life-changing surgery, according to a landmark study presented at the American Society of Clinical Oncology’s annual meeting in Chicago. This innovative approach, combining chemoradiation with the immunotherapy drug durvalumab, offers a significant improvement in outcomes for patients with advanced bladder cancer, potentially allowing them to avoid the notoriously brutal procedure of full bladder removal.
Bladder cancer affects approximately 11,000 individuals in the UK annually, with one in four cases presenting as an advanced form where the tumour has penetrated the muscle wall. Historically, the standard treatment for these aggressive cases has been radical cystectomy – the complete surgical removal of the bladder. This operation carries severe, life-altering consequences, as famously recounted by artist Tracey Emin, 62, who underwent the procedure in 2020 for severe squamous bladder cancer. Emin described the profound impact of living with a urostomy bag, noting, “It’s a very private thing because, basically, you’ve got part of your bodily function happening on the outside of your body. It leaks and things happen. I could be out somewhere public and it could happen — and people’d just think I’ve pissed myself or think I’ve been drinking. Not being able to urinate and to have a bag of piss attached to you for the rest of your life is hardcore.”
Immunotherapy Enhances Bladder Cancer Treatment
Previous research has explored non-surgical alternatives, demonstrating that a combination of chemotherapy and radiotherapy could reduce the risk of cancer recurrence, though around 40% of patients still saw their cancer return within a year. The new trial, led by Professor Nick James, an expert in prostate and bladder cancer at The Institute of Cancer Research (ICR) in London, involved 54 patients. The addition of durvalumab, an immunotherapy drug, to the chemoradiation regimen yielded striking results: 46 patients (85%) remained cancer-free one year later.
“We’ve shown that with the addition of immunotherapy, the combination of treatments has an even bigger improvement in outcomes — fewer cancers come back. Importantly, it’s possible to achieve these outcomes without surgically removing the bladder. Keeping the bladder means people can avoid major, life-changing surgery and maintain more of their normal daily function and independence.”
Professor James, also a consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, anticipates that this approach will be “practice-changing,” offering improved outcomes while preserving patients’ quality of life. Durvalumab functions by blocking a protein that cancer cells exploit to evade the immune system. The drug has already received NHS approval for bladder cancer when used in conjunction with surgery and chemotherapy, but these latest findings suggest that surgery could potentially be omitted for certain patients, marking a significant advancement in cancer care.
Professor Kristian Helin, ICR chief executive, emphasized the broader implications of these findings for health and wellness. “Identifying smarter, kinder treatments is a key priority in cancer research — approaches that not only control the disease effectively, but that also reduce the life-changing impact of treatment on patients,” he stated. “These results are a significant step forward for people with aggressive bladder cancer. By adding immunotherapy to chemotherapy and radiotherapy, we may be able to spare patients the physical and psychological burden of having their bladder removed entirely and after one year, we’re already seeing a meaningful reduction in the risk of the cancer returning.”
Michelle Mitchell, chief executive of Cancer Research UK, echoed this sentiment, highlighting the critical need for less invasive treatments. “Radical surgery can cause serious side effects for bladder cancer patients. Finding kinder ways to treat the disease is incredibly important, and this trial has done exactly that,” she noted. While acknowledging that further research on a larger scale will be necessary, Mitchell believes these results have the potential to be truly life-changing for some bladder cancer patients. This breakthrough treatment combination underscores a growing trend in oncology towards personalized, less debilitating therapies that prioritize both efficacy and patient quality of life.
The integration of immunotherapy into existing chemoradiation protocols represents a pivotal shift in the management of advanced bladder cancer. This innovative approach promises not only extended cancer-free periods but also a profound improvement in the daily lives of patients, allowing them to retain bodily function and independence. As the medical community moves forward, the focus will undoubtedly be on validating these findings in larger trials and making this kinder, smarter bladder cancer treatment accessible to all eligible patients.
